Breast Cancer Clinical Advisory Board

Arnold Baskies, MD, FACS

Dr. Baskies is a specialist in surgical oncology and general surgery, affiliated with Virtua Health Systems.  He is former Chairman of the National Board of Directors of the American Cancer Society and current Chair of the society’s Global Cancer Control Advisory Council.  He is a member of the Global Breast ...

Read More

G. Thomas Budd, MD, FACP

Dr. Budd is a specialist in breast cancer and the principal investigator of the Cleveland Clinic and Anixa partnered Phase 1 trial of the Breast Cancer Vaccine.  He is Professor of Medicine in the Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Cancer Center, and Professor in the ...

Read More

Brian Leyland-Jones, MBBS, MD, Ph.D., FACP, FRCPC

Dr. Leyland-Jones is a pre-eminent clinical trialist in oncology and the recipient of numerous awards.  He is the Chief Medical Officer of AIM-HI Accelerator Fund, OTraces, and the N OF 1 Mission.  In addition, he is a Scientific Advisory Board Member of the National Foundation for Cancer Research and NED ...

Read More

Hope Rugo, MD, FASCO

Dr. Rugo is a leader and specialist in breast cancer research and recipient of numerous awards.  She is Professor, Department of Medicine (Hematology/Oncology), and Director, Breast Oncology and Clinical Trials Education, at the UCSF Helen Diller Family Comprehensive Cancer Center.  She is Co-chair of the Triple Negative Working Group, a member ...

Read More

Stephen Schoenberger, PH.D.

Dr. Schoenberger is a translational immunologist working in the area of precision cancer immunotherapy.  He is a professor in the Center for Cancer Immunotherapy at the La Jolla institute for Immunology and Adjunct Professor of Medicine in the Division of Hematology and Oncology at the UC San Diego Moores Cancer ...

Read More

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus

Latest News & Events

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

Read More...

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025

Read More...

Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

Read More...